Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German biotech company Evotec has scrapped a phase one trial into Alzheimer's drug EVT 301 after adverse effects in some volunteers were found.
Subscribe to our email newsletter
During the one month safety and tolerability study for the drug, several cases of asymptomatic elevated liver function tests in the group of elderly volunteers were observed. No cases were found in the young healthy volunteer group. In light of the findings, Evotech has halted the trial and has discontinued the development program.
“The discontinuation of the EVT 301 program will free up E20 million, which will provide us a lot of flexibility in developing our pipeline,” said Joern Aldag, president and CEO of Evotec.
“We continue to believe there is ample opportunity in our current proprietary portfolio of CNS candidates, including our insomnia drug EVT 201 and the potential of EVT 101 for the treatment of Alzheimer’s disease, neuropathic pain or other indications,” Mr Aldag added.